Search Results
171 Results Found for “drug therapy”
Dr Jonathan Piccini discusses rhythm control in patients with atrial fibrillation and heart failure with preserved ejection fraction, the growing role of catheter ablation, and the evidence still needed to define its impact on cardiovascular outcomes.
Prof. Thomas Thum discusses Phase II findings from the HF-REVERT study, what they suggest about patient selection for RNA-based therapies, and how these approaches could offer new ways to treat heart failure.
Professor Arnoud van ’t Hof discusses the CELEBRATE trial, the potential benefits of administering antiplatelet therapy before patients with STEMI reach the catheterization laboratory, and what would be needed to translate this approach into clinical practice.
Phase IIb LUMINARA data presented at ESC Congress 2026 suggest that AZD5462 may improve cardiac remodeling and hemodynamics across different heart failure phenotypes, with the lowest dose producing the strongest remodeling signal in HFrEF.
Prof. Adriaan Voors discusses the evolving role of GLP-1 receptor agonists in heart failure, the importance of patient selection and monitoring, and how emerging evidence and new guidelines could influence clinical practice.
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
Arrowhead Pharmaceuticals, Inc. (Pasadena, CA) has reported topline results from two phase III trials evaluating plozasiran in adults with severe hypertriglyceridemia (sHTG), according to a recent press release.1 Plozasiran, an siRNA therapy directed against apolipoprotein C-III (APOC3) messenger RNA, is already approved as Redemplo for adults with familial chylomicronemia syndrome but remains investigational for the broader sHTG population.
The FDA has granted orphan drug designation to AFTX-201 (Affinia Therapeutics; Waltham, MA), an investigational gene therapy, for the treatment of BAG3-associated dilated cardiomyopathy (BAG3-DCM), according to the company. The designation follows a recent FDA Fast Track designation for the same program.
Native valve infective endocarditis (IE) is rare, with an incidence of 3–7 cases per 100,000 person-years.1,2 Cardiac structural complications from local infection extension include valvular destruction, peri-annular abscess and fistula formation. Left ventricular pseudoaneurysm (LVP) from IE is exceedingly rare, occurring in &...
Longer diagnosis-to-ablation time (DAT) was associated with a higher risk of atrial arrhythmia recurrence following de novo radiofrequency catheter ablation (RFA) for atrial fibrillation (AF), according to a prospective, multicenter cohort study published in JAMA Network Open.1
At EHRA 2026, Professor Claudio Tondo presents his highlights on advances in ablation and device technologies, led by pulsed field ablation, showcasing a rapidly evolving landscape in the treatment of complex arrhythmias.
Ventricular fibrillation (VF) is characterized by rapid (>300 beats a per minute), irregular electrical activation with variable electrocardiographic waveforms that prevents coordinated myocardial contraction, resulting in immediate loss of cardiac output.1 It most commonly occurs in the context of coronary ...
Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...
Day 2 hotline data at EuroPCR 2026 highlighted improved outcomes with FFR-guided PCI in TAVI, comparable 10-year survival with PCI and CABG in left main disease and consistent LAAC benefits across age groups.
Data presented on the first day of EuroPCR 2026, Paris, highlighted continued advances in lipid lowering, coronary scaffold technology and vessel restoration strategies. From substantial reductions in cardiovascular events with aggressive LDL-cholesterol lowering to encouraging long-term outcomes with next-generation bioresorbable and adaptive coronary devices, these studies offered important insights into the future direction of PCI and secondary prevention.
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
At ACC26, Dr Mardi Gomberg-Maitland presented results from the CADENCE trial, showing how sotatercept significantly improves pulmonary hemodynamics in HFpEF-associated pulmonary hypertension, offering hope for the first targeted therapy in this high-risk population.
Late-breaking data from the Phase 3 HOPE-3 trial of deramiocel in Duchenne muscular dystrophy, presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, suggest potential benefits across cardiac and functional outcomes. The investigational first-in-class therapy is currently under review by the FDA for the treatment of DMD cardiomyopathy, with a Prescription Drug User Fee Act target action date of 22 August, 2026.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
